On July 27, 2019, Dr. Rafael Amado, President, Research and Development of Adaptimmune Therapeutics plc informed the Company that he will be leaving the Company effective August 12, 2019. On August 1, 2019, the Company announced the appointment of John Lunger as Chief Patient Supply Officer effective August 1, 2019, and the creation of a new executive team. Effective from September 1, 2019, the new executive team will comprise Adrian Rawcliffe, Chief Executive Officer, Bill Bertrand, Chief Operating Officer, Helen Tayton-Martin, Chief Business Officer, and John Lunger, Chief Patient Supply Officer. As announced on June 27, 2019, the Company has started a global search for a new Chief Financial Officer (CFO), which will be the subject of a separate announcement. Until a replacement is found, Mr. Rawcliffe will continue in his role as the Company’s CFO, principal financial officer and principal accounting officer.